Physician profile
Eric Arthur Carlson
NPI 1417926015
$14,244.11
in general payments reported to CMS, 2019-2025
73 companies · $2,293 in 2025
The $2,293 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $1,557 · 2021: $3,188 · 2022: $2,145 · 2023: $2,180 · 2024: $1,930 · 2025: $2,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,116 · Education: $180 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,115.50 |
| Education | $179.74 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $107.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $942.94 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $905.06 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $869.29 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $840.43 | 2021-2025 | Xpovio |
| E.R. Squibb & Sons, L.L.C. | $833.43 | 2019-2025 | Reblozyl, Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals Lp | $819.32 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Daiichi Sankyo INC. | $592.53 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Genzyme Corporation | $504.81 | 2019-2025 | |
| Verity Pharmaceuticals INC. | $500.00 | 2021 | |
| Janssen Biotech, INC. | $497.67 | 2019-2025 | Rybrevant, Erleada, Darzalex |
| Genentech USA, INC. | $371.57 | 2019-2025 | Polivy, Columvi, Lunsumio |
| Amgen INC. | $352.80 | 2019-2024 | Prolia, Lumakras |
| Regeneron Healthcare Solutions, INC. | $322.17 | 2021-2025 | Libtayo |
| Abbvie INC. | $311.36 | 2019-2025 | Venclexta |
| Celgene Corporation | $262.43 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $261.83 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Merck Sharp & Dohme LLC | $255.38 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Glaxosmithkline, LLC. | $254.26 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Astellas Pharma US INC | $252.27 | 2019-2025 | Padcev, Vyloy, Xospata |
| Emd Serono, INC. | $235.66 | 2022-2025 | Bavencio |
| Lilly USA, LLC | $230.80 | 2019-2025 | Jaypirca, Retevmo, Verzenio |
| Genentech, INC. | $214.69 | 2024-2025 | Tecentriq, Alecensa, Tecentriq Hybreza |
| Gilead Sciences, INC. | $214.05 | 2021-2025 | Trodelvy |
| Incyte Corporation | $213.85 | 2022-2025 | Jakafi, Monjuvi, Niktimvo |
| Kite Pharma, INC. | $204.74 | 2020-2023 | |
| Exelixis INC. | $191.41 | 2021-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $173.31 | 2022-2025 | Iclusig, Ninlaro, Alunbrig |
| Eisai INC. | $165.77 | 2019-2025 | |
| Galvanize Therapeutics, INC | $156.27 | 2023 | Aliya System |
| Bayer Healthcare Pharmaceuticals INC. | $151.47 | 2021-2025 | |
| Seagen INC. | $142.56 | 2019-2023 | Padcev |
| Aveo Pharmaceuticals, INC. | $130.45 | 2021-2023 | Fotivda |
| Beone Medicines USA, INC. | $124.59 | 2025 | Brukinsa |
| Janssen Scientific Affairs, LLC | $115.55 | 2024-2025 | Tecvayli, Talvey, Darzalex |
| Foundation Medicine, INC. | $107.15 | 2023 | |
| Sobi, INC | $105.97 | 2022-2024 | |
| Epizyme, INC. | $102.20 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.88 | 2021-2025 | Gilotrif |
| Beigene USA, INC. | $85.53 | 2020-2022 | |
| Genmab U.S., INC. | $82.21 | 2024-2025 | Tivdak |
| Taiho Oncology, INC. | $71.17 | 2019-2024 | |
| Puma Biotechnology, INC. | $66.77 | 2020-2024 | |
| Acrotech Biopharma INC. | $64.53 | 2021 | |
| Mylan Institutional INC. | $62.10 | 2022-2023 | Ogivri, Fulphila |
| Blueprint Medicines Corporation | $53.69 | 2021-2025 | Ayvakit |
| Pharmacyclics LLC, An Abbvie Company | $48.78 | 2021-2022 | |
| Blue Earth Diagnostics | $47.59 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $46.71 | 2024-2025 | Monoferric, Cosela |
| Kyowa Kirin, INC. | $46.15 | 2020-2025 | |
| G1 Therapeutics, INC. | $34.96 | 2022 | |
| Alexion Pharmaceuticals, INC. | $34.52 | 2022 | |
| Jazz Pharmaceuticals INC. | $34.27 | 2025 | |
| Agios Pharmaceuticals, INC. | $33.65 | 2022 | |
| Aurobindo Pharma USA, INC. | $30.00 | 2020 | |
| Allergan, INC. | $29.87 | 2019 | |
| Springworks Therapeutics, INC. | $28.92 | 2025 | Ogsiveo |
| Pharmaessentia USA Corporation | $25.80 | 2023 | Besremi |
| Coherus Oncology, INC. | $21.87 | 2025 | Udenyca |
| Sumitomo Pharma America, INC. | $21.75 | 2024 | Orgovyx |
| Tolmar, INC. | $21.23 | 2023 | |
| Bioventus LLC | $20.98 | 2019 | |
| Adma Biomanufacturing LLC | $20.90 | 2022 | |
| Servier Pharmaceuticals LLC | $19.36 | 2022 | |
| Medtronic, INC. | $18.14 | 2023 | Synchromedii |
| Novocure INC. | $17.74 | 2025 | Optune Lua (Novottf-200t) |
| Apellis Pharmaceuticals, INC. | $17.57 | 2024 | Empaveli |
| Dova Pharmaceuticals | $16.77 | 2021 | |
| Stemline Therapeutics INC. | $16.43 | 2023 | Orserdu |
| Lexicon Pharmaceuticals, INC. | $15.75 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $15.56 | 2023 | Tazverik |
| Mirati Therapeutics, INC. | $14.31 | 2023 | Krazati |
| Sun Pharmaceutical Industries INC. | $13.60 | 2022 | |
| Cti Biopharma Corp. | $13.01 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.